Hikal begins commercial production of personal care products at Panoli
- Hikal Limited started commercial production at its new cGMP facility in Panoli, Gujarat on September 22, 2026
- The facility targets the global beauty sector with a focus on second-generation UV filters for skincare
- Initial product samples received positive validation feedback from customers, indicating strong market interest
- The move diversifies Hikal's portfolio beyond pharmaceuticals and crop protection into specialty ingredients
*this image is generated using AI for illustrative purposes only.
Hikal Limited has announced the commencement of commercial production for its personal care products at a new cGMP-compliant facility in Panoli, Gujarat. The milestone on September 22, 2026, marks the company's formal entry into commercial-scale supply for the global beauty and personal care industry.
The new multipurpose facility was created by repurposing an existing manufacturing asset to meet the specific regulatory and quality standards of the beauty sector. Hikal leveraged its decades of experience in process chemistry and regulatory manufacturing to transition this capability into a new customer base. The facility has already manufactured its first production batches, with product samples validated by customers receiving positive feedback that indicates strong initial market pull.
Strategic focus on skincare ingredients
Hikal's initial strategy within the personal care segment targets the skin care category, where global demand is accelerating. The company has developed a portfolio focused on second-generation UV filters, designed to offer enhanced performance and align with tightening regulatory requirements in key international markets. These products are currently undergoing approval processes with global customers, representing a diversification beyond Hikal's core pharmaceuticals and crop protection businesses.
Sameer Hiremath, Vice Chairman and Managing Director, stated that the commissioning of the Panoli facility and the subsequent customer validation reflect a disciplined approach similar to that used in building their established segments. He noted that the combination of deep customer partnerships, rigorous quality systems, and patient capital investment positions the business for growth in the coming years.
Capability expansion and sustainability
This development is part of a broader pattern of capability building across Hikal's platform. Recently, the company also commissioned a new cGMP pilot plant at its Pune Research & Technology campus. This facility is intended to strengthen pharmaceutical process development and scale-up capabilities, supporting the growth of its CDMO (Contract Development and Manufacturing Organization) business.
The announcement follows Hikal's receipt of an EcoVadis Gold Medal rating for sustainability excellence. The company achieved an overall score of 84/100, placing it in the 97th percentile among more than 175,000 companies assessed globally. This recognition underscores Hikal's commitment to responsible manufacturing and sustainable procurement across its operations.
| Facility | Location | Purpose | Status |
|---|---|---|---|
| Personal Care Plant | Panoli, Gujarat | Commercial production of UV filters | Operational |
| Pilot Plant | Pune, Maharashtra | Pharma process development and scale-up | Commissioned |
What the numbers show
The EcoVadis score of 84/100 and the 97th percentile ranking provide a quantifiable metric of Hikal's operational compliance and sustainability standing relative to its global peers. While the source does not disclose revenue figures for the new segment, the explicit linkage of the Panoli facility's output to "second-generation UV filters" highlights a strategic pivot toward high-value specialty ingredients rather than commodity chemicals. This aligns with the company's existing strength in regulated markets, suggesting that the new revenue stream will likely depend on successful regulatory approvals from global customers rather than immediate volume sales.
Historical Stock Returns for Hikal
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.10% | +1.96% | +6.38% | +36.14% | -14.86% | -64.24% |
What specific regulatory approvals are pending for Hikal's second-generation UV filters, and what is the expected timeline for their commercialization in key markets like the EU and US?
How will the new Panoli facility's capacity utilization rates impact Hikal's overall EBITDA margins as the personal care segment scales up from initial batches?
Which major global beauty brands have provided positive feedback on the initial product samples, and does this indicate potential for long-term supply contracts?
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
